PE20120328A1 - Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh - Google Patents
Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodhInfo
- Publication number
- PE20120328A1 PE20120328A1 PE2011001597A PE2011001597A PE20120328A1 PE 20120328 A1 PE20120328 A1 PE 20120328A1 PE 2011001597 A PE2011001597 A PE 2011001597A PE 2011001597 A PE2011001597 A PE 2011001597A PE 20120328 A1 PE20120328 A1 PE 20120328A1
- Authority
- PE
- Peru
- Prior art keywords
- trometamine
- acid
- salt
- benzoic
- amino
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 title 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 PHENYL GROUP Chemical group 0.000 abstract 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical class [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UNA SAL DE ADICION CRISTALINA DE TROMETAMINA CON UN DERIVADO DE ACIDO DE AZABIFENILAMINOBENZOICO DE FORMULA (I), DONDE R1 ES ALQUILO C1-C4, CICLOALQUILO C3-C4 Y CF3; G1 ES N, CH, C(CH3) O C(CF3); G2 ES UN GRUPO FENILO OPCIONALMENTE SUSTITUIDO CON CLORO, FLUORO, METOXI, ETOXI, ISOPROPOXI, TRIFLUOROMETOXI, CF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: SAL DE TROMETAMINA DE ACIDO 5-CICLOPROPIL-2-{[2-(2,6-DIFLUOROFENIL)PIRIMIDIN-5-IL]AMINO}BENZOICO, SAL DE TROMETAMINA DE ACIDO 5-CICLOPROPIL-2-{[2-(2-(TRIFLUOROMETIL)FENIL)PIRIMIDIN-5-IL]AMINO}BENZOICO, SAL DE TROMETAMINA DE ACIDO 5-METIL-2-{[6-(2,3-DIFLUOROFENIL)PIRIDIN-3-IL]AMINO}BENZOICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHAS SALES INHIBEN LA DIHIDROOROATO DESHIDROGENASA (DHODH) Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, PSORIASIS, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382032A EP2230232A1 (en) | 2009-03-13 | 2009-03-13 | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120328A1 true PE20120328A1 (es) | 2012-03-29 |
Family
ID=40671396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001597A PE20120328A1 (es) | 2009-03-13 | 2010-03-11 | Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120003183A1 (es) |
| EP (2) | EP2230232A1 (es) |
| JP (1) | JP2012520251A (es) |
| KR (1) | KR20110126695A (es) |
| CN (1) | CN102341372A (es) |
| AR (1) | AR075737A1 (es) |
| AU (1) | AU2010223527A1 (es) |
| CA (1) | CA2754785A1 (es) |
| CL (1) | CL2011002213A1 (es) |
| CO (1) | CO6501157A2 (es) |
| EA (1) | EA201101298A1 (es) |
| EC (1) | ECSP11011384A (es) |
| IL (1) | IL214517A0 (es) |
| MX (1) | MX2011009147A (es) |
| NZ (1) | NZ594491A (es) |
| PE (1) | PE20120328A1 (es) |
| SG (2) | SG173824A1 (es) |
| TW (1) | TW201033177A (es) |
| UY (1) | UY32465A (es) |
| WO (1) | WO2010102825A1 (es) |
| ZA (1) | ZA201105743B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| SMT202100553T1 (it) | 2017-04-24 | 2021-11-12 | Aurigene Discovery Tech Ltd | Metodi d'uso per derivati benzotriazolici trisostituiti come inibitori di diidroorotato ossigenasi |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| CN110903219A (zh) * | 2018-09-18 | 2020-03-24 | 广东东阳光药业有限公司 | 酰胺衍生物的盐及其制备方法 |
| MX2021007536A (es) * | 2018-12-21 | 2021-09-23 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo. |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| DE60226855D1 (de) | 2001-04-05 | 2008-07-10 | Aventis Pharma Inc | Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose |
| WO2002102374A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Amine salt of an integrin receptor antagonist |
| MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056747A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| MXPA06013435A (es) | 2004-05-21 | 2007-03-23 | Uab Research Foundation | Composiciones y metodos referentes a inhibidores de sintesis de pirimidina. |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006044741A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2009
- 2009-03-13 EP EP09382032A patent/EP2230232A1/en not_active Withdrawn
-
2010
- 2010-02-24 UY UY0001032465A patent/UY32465A/es unknown
- 2010-03-08 TW TW099106618A patent/TW201033177A/zh unknown
- 2010-03-11 SG SG2011060829A patent/SG173824A1/en unknown
- 2010-03-11 AR ARP100100740A patent/AR075737A1/es not_active Application Discontinuation
- 2010-03-11 EA EA201101298A patent/EA201101298A1/ru unknown
- 2010-03-11 JP JP2011553359A patent/JP2012520251A/ja active Pending
- 2010-03-11 SG SG10201400568PA patent/SG10201400568PA/en unknown
- 2010-03-11 CA CA2754785A patent/CA2754785A1/en not_active Abandoned
- 2010-03-11 PE PE2011001597A patent/PE20120328A1/es not_active Application Discontinuation
- 2010-03-11 AU AU2010223527A patent/AU2010223527A1/en not_active Abandoned
- 2010-03-11 WO PCT/EP2010/001549 patent/WO2010102825A1/en not_active Ceased
- 2010-03-11 KR KR1020117021320A patent/KR20110126695A/ko not_active Withdrawn
- 2010-03-11 US US13/256,104 patent/US20120003183A1/en not_active Abandoned
- 2010-03-11 NZ NZ594491A patent/NZ594491A/xx not_active IP Right Cessation
- 2010-03-11 EP EP10708733A patent/EP2406222A1/en not_active Withdrawn
- 2010-03-11 CN CN2010800108779A patent/CN102341372A/zh active Pending
- 2010-03-11 MX MX2011009147A patent/MX2011009147A/es not_active Application Discontinuation
-
2011
- 2011-08-04 ZA ZA2011/05743A patent/ZA201105743B/en unknown
- 2011-08-08 IL IL214517A patent/IL214517A0/en unknown
- 2011-09-01 CO CO11112331A patent/CO6501157A2/es active IP Right Grant
- 2011-09-08 CL CL2011002213A patent/CL2011002213A1/es unknown
- 2011-10-07 EC EC2011011384A patent/ECSP11011384A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012520251A (ja) | 2012-09-06 |
| UY32465A (es) | 2010-05-31 |
| AR075737A1 (es) | 2011-04-20 |
| CN102341372A (zh) | 2012-02-01 |
| ZA201105743B (en) | 2012-04-25 |
| CL2011002213A1 (es) | 2012-03-09 |
| CA2754785A1 (en) | 2010-09-16 |
| TW201033177A (en) | 2010-09-16 |
| US20120003183A1 (en) | 2012-01-05 |
| SG173824A1 (en) | 2011-09-29 |
| IL214517A0 (en) | 2011-09-27 |
| WO2010102825A1 (en) | 2010-09-16 |
| AU2010223527A1 (en) | 2011-08-25 |
| CO6501157A2 (es) | 2012-08-15 |
| ECSP11011384A (es) | 2011-11-30 |
| SG10201400568PA (en) | 2014-07-30 |
| EP2406222A1 (en) | 2012-01-18 |
| EA201101298A1 (ru) | 2012-04-30 |
| NZ594491A (en) | 2013-11-29 |
| MX2011009147A (es) | 2011-09-15 |
| EP2230232A1 (en) | 2010-09-22 |
| KR20110126695A (ko) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120328A1 (es) | Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh | |
| PE20090903A1 (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa | |
| PE20090361A1 (es) | Acidos benzoilamino-indan-2-carboxilicos sustituidos como inhibidores de cxcr5 | |
| PE20141726A1 (es) | Heterociclilaminas como inhibidores de pi 3k | |
| PE20141050A1 (es) | Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina | |
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20120171A1 (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh | |
| PE20091002A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| PE20140188A1 (es) | Co-cristales y sales de inhibidores de ccr3 | |
| PE20120552A1 (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| EA201201378A1 (ru) | Определенные аминопиримидины, композиции на их основе и способы их использования | |
| CL2012000001A1 (es) | Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros. | |
| PE20141409A1 (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| PE20081888A1 (es) | ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3 | |
| PE20120505A1 (es) | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a | |
| PE20091828A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2 | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20121335A1 (es) | Compuestos derivados de amida como inhibidores de raf cinasas | |
| UA111869C2 (uk) | Сполуки 2-(заміщений феніл)-циклопентан-1,3-діону та їх похідні | |
| PE20080552A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
| UY33226A (es) | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 | |
| PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |